TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
USA - NASDAQ:TMDX - US89377M1099 - Common Stock
135.79 USD
+1.47 (+1.09%)
135.046 USD
-0.74 (-0.55%)
TMDX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. TMDX has only an average score on both its financial health and profitability. TMDX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.05%, TMDX belongs to the top of the industry, outperforming 91.53% of the companies in the same industry.
Looking at the Return On Equity, with a value of 22.53%, TMDX belongs to the top of the industry, outperforming 94.71% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 7.25%, TMDX belongs to the top of the industry, outperforming 83.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.05% | ||
| ROE | 22.53% | ||
| ROIC | 7.25% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 13.49%, TMDX belongs to the top of the industry, outperforming 89.95% of the companies in the same industry.
The Operating Margin of TMDX (14.41%) is better than 84.13% of its industry peers.
Looking at the Gross Margin, with a value of 59.79%, TMDX is in line with its industry, outperforming 59.79% of the companies in the same industry.
TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.41% | ||
| PM (TTM) | 13.49% | ||
| GM | 59.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, TMDX has more shares outstanding
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.71 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX has a better Altman-Z score (5.71) than 82.01% of its industry peers.
TMDX has a debt to FCF ratio of 29.44. This is a negative value and a sign of low solvency as TMDX would need 29.44 years to pay back of all of its debts.
The Debt to FCF ratio of TMDX (29.44) is better than 68.25% of its industry peers.
TMDX has a Debt/Equity ratio of 1.61. This is a high value indicating a heavy dependency on external financing.
TMDX has a Debt to Equity ratio of 1.61. This is amonst the worse of the industry: TMDX underperforms 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.61 | ||
| Debt/FCF | 29.44 | ||
| Altman-Z | 5.71 |
ROIC/WACC0.9
WACC8.03%
2.3 Liquidity
A Current Ratio of 9.86 indicates that TMDX has no problem at all paying its short term obligations.
TMDX's Current ratio of 9.86 is amongst the best of the industry. TMDX outperforms 92.59% of its industry peers.
A Quick Ratio of 9.10 indicates that TMDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.10, TMDX belongs to the top of the industry, outperforming 92.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.86 | ||
| Quick Ratio | 9.1 |
3. Growth
3.1 Past
TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
The Revenue has grown by 82.74% in the past year. This is a very strong growth!
Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 79.64% on average per year.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.23%
3.2 Future
The Earnings Per Share is expected to grow by 42.56% on average over the next years. This is a very strong growth
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.19% on average per year.
EPS Next Y138.61%
EPS Next 2Y66.6%
EPS Next 3Y53.82%
EPS Next 5Y42.56%
Revenue Next Year39.65%
Revenue Next 2Y29.86%
Revenue Next 3Y25.94%
Revenue Next 5Y21.19%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 54.98, TMDX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 67.72% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.19. TMDX is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 48.44, TMDX can be considered very expensive at the moment.
68.78% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (22.50), we can say TMDX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.98 | ||
| Fwd PE | 48.44 |
4.2 Price Multiples
67.20% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
TMDX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 68.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 266.77 | ||
| EV/EBITDA | 46.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.82% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y66.6%
EPS Next 3Y53.82%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
135.79
+1.47 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change0.11%
Ins Owners2.96%
Ins Owner Change2.28%
Market Cap4.63B
Revenue(TTM)441.54M
Net Income(TTM)71.66M
Analysts81.11
Price Target149.33 (9.97%)
Short Float %24.1%
Short Ratio8.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.71%
Min EPS beat(2)100.04%
Max EPS beat(2)167.38%
EPS beat(4)3
Avg EPS beat(4)55.99%
Min EPS beat(4)-59.86%
Max EPS beat(4)167.38%
EPS beat(8)6
Avg EPS beat(8)145.25%
EPS beat(12)10
Avg EPS beat(12)114.95%
EPS beat(16)11
Avg EPS beat(16)83.13%
Revenue beat(2)2
Avg Revenue beat(2)9.07%
Min Revenue beat(2)4.34%
Max Revenue beat(2)13.8%
Revenue beat(4)3
Avg Revenue beat(4)4.75%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.8%
Revenue beat(8)7
Avg Revenue beat(8)11.77%
Revenue beat(12)11
Avg Revenue beat(12)15.17%
Revenue beat(16)14
Avg Revenue beat(16)17.24%
PT rev (1m)0%
PT rev (3m)-2.25%
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)12.82%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)30.79%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)3.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.98 | ||
| Fwd PE | 48.44 | ||
| P/S | 8.71 | ||
| P/FCF | 266.77 | ||
| P/OCF | 40.16 | ||
| P/B | 14.55 | ||
| P/tB | 15.2 | ||
| EV/EBITDA | 46.75 |
EPS(TTM)2.47
EY1.82%
EPS(NY)2.8
Fwd EY2.06%
FCF(TTM)0.51
FCFY0.37%
OCF(TTM)3.38
OCFY2.49%
SpS15.58
BVpS9.33
TBVpS8.93
PEG (NY)0.4
PEG (5Y)N/A
Graham Number22.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.05% | ||
| ROE | 22.53% | ||
| ROCE | 9.18% | ||
| ROIC | 7.25% | ||
| ROICexc | 13.96% | ||
| ROICexgc | 14.41% | ||
| OM | 14.41% | ||
| PM (TTM) | 13.49% | ||
| GM | 59.79% | ||
| FCFM | 3.27% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.61 | ||
| Debt/FCF | 29.44 | ||
| Debt/EBITDA | 5.09 | ||
| Cap/Depr | 412.74% | ||
| Cap/Sales | 18.43% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.93% | ||
| Profit Quality | 24.21% | ||
| Current Ratio | 9.86 | ||
| Quick Ratio | 9.1 | ||
| Altman-Z | 5.71 |
F-Score7
WACC8.03%
ROIC/WACC0.9
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y138.61%
EPS Next 2Y66.6%
EPS Next 3Y53.82%
EPS Next 5Y42.56%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.23%
Revenue Next Year39.65%
Revenue Next 2Y29.86%
Revenue Next 3Y25.94%
Revenue Next 5Y21.19%
EBIT growth 1Y6324.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.38%
FCF growth 1Y142.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y451.66%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 54.98 and the Price/Book (PB) ratio is 14.55.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.